Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
3 verified discoveries match your filters.
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed
A specific expanded FDA approval exists for trastuzumab deruxtecan in a defined HR-positive, HER2-low/ultralow metastatic breast cancer population after endocrine therapy, based on a significant progression-free-survival benefit in DESTINY-Breast06.
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly delayed disease progression compared with palbociclib and fulvestrant alone, in a PIK3CA-mutated, endocrine-resistant, first-line metastatic breast…
Primary source cited
Last reviewed